EUVIMEDEUVIMED entdecken
Crossref

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients

Yundi Zhang iD, Yue Du iD, Shuyu Ren, Yue Li, Xiaoming Zhang, Xiaohong Cao, Fengxi Liu, Huiying Zong, Yan Li

Annals of Pharmacotherapy · 2024-06 · 58 (6) · 605-613

DOI: 10.1177/10600280231197399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 13.09.2023. Verfasst von Yundi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University of Traditional Chinese Medicine, Jinan, China. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation, Cytochrome P-450 CYP3A, Voriconazole. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Drug Risk Management Project: Diabetes Drug Risk Management Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effect of drug-drug interaction (DDI) between tacrolimus and voriconazole on the pharmacokinetics of tacrolimus in different CYP3A5 genotypes has not been reported in previous studies.

Objective

The objective of this study was to investigate whether CYP3A5 genotype could influence tacrolimus-voriconazole DDI in Chinese kidney transplant patients.

Methods

All kidney transplant patients were divided into combination and non-combination groups based on whether tacrolimus was combined with or without voriconazole. Each group was subdivided into CYP3A5 expresser ( CYP3A5*1/*1 or CYP3A5*1/*3) and CYP3A5 nonexpresser ( CYP3A5*3/*3). A retrospective analysis compared tacrolimus dose (D)-corrected trough concentrations (C 0 ) (C 0 /D) between combination and non-combination groups, respectively. Tacrolimus C 0 /D was also compared between CYP3A5 expresser and nonexpresser in both groups.

Results

The C 0 /D values of tacrolimus were significantly different between CYP3A5 expresser and nonexpresser in combination group (378.20 [219.38, 633.48] ng/mL/[mg/kg/d] vs 720.00 [595.35, 1681.50] ng/mL/[mg/kg/d], P = 0.0010). Either in C YP3A5 expresser or nonexpresser, we found a statistically significant difference in tacrolimus C 0 /D between combination and non-combination group ( P < 0.0001). The increase in CYP3A5 nonexpresser was 1.38 times higher than that in CYP3A5 expresser (320.93% vs 232.19%). Conclusion and Relevance: The median C 0 /D values were 90.38% higher in kidney transplant recipients with CYP3A5*3/*3 genotype than in those with CYP3A5*1/*1 or CYP3A5*1/*3 genotype when treated with both tacrolimus and voriconazole. A CYP3A5 genotype-dependent DDI was found between tacrolimus and voriconazole. Therefore, personalized therapy accounting for CYP3A5 genotype detection and therapeutic drug monitoring is necessary for kidney transplant patients when treating with tacrolimus and voriconazole.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusKidney TransplantationCytochrome P-450 CYP3AVoriconazoleDrug InteractionsImmunosuppressive AgentsGenotypeHumansMaleFemaleRetrospective StudiesAdultMiddle AgedAntifungal AgentsEast Asian People

Stichwörter der Autor:innen

CYP3A5drug-drug interactionkidney transplanttacrolimusvoriconazole

Substanzen

TacrolimusCytochrome P-450 CYP3AVoriconazoleCYP3A5 protein, humanImmunosuppressive AgentsAntifungal Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, China.
  • Jinan Xinhang Experimental Foreign Language School, Jinan, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
  • Urinary Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.

ORCID-Profile: Yundi Zhang, Yue Du

Förderung

  • Drug Risk Management Project: Diabetes Drug Risk Management Research

Zitieren

APA

Zhang, Y., Du, Y., Ren, S., Li, Y., Zhang, X., Cao, X., Liu, F., Zong, H., & Li, Y. (2024). CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients. Annals of Pharmacotherapy, 58(6), 605-613. https://doi.org/10.1177/10600280231197399

Vancouver

Zhang Y, Du Y, Ren S, Li Y, Zhang X, Cao X, et al. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients. Annals of Pharmacotherapy. 2024;58(6):605-613. doi:10.1177/10600280231197399

BibTeX
@article{Zhang2024,
  author = {Zhang, Yundi and Du, Yue and Ren, Shuyu and Li, Yue and Zhang, Xiaoming and Cao, Xiaohong and Liu, Fengxi and Zong, Huiying and Li, Yan},
  title = {CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  volume = {58},
  number = {6},
  pages = {605--613},
  doi = {10.1177/10600280231197399}
}
Kostenlos starten →